Table 3.

Effect of geographical region on efficacy at week 12 for NA versus non-NA patients

Response criterion	Odds ratio (95% CI)
IGA 0/1	1.28 (0.86–1.90)
IGA 0	1.77 (1.14–2.72)
PASI 75	1.10 (0.67–1.82)
PASI 90	1.14 (0.77–1.68)
PASI 100	1.61 (1.02–2.54)

CI confidence interval, IGA Investigator’s Global Assessment, NA North American, PASI Psoriasis Area and Severity Index

The odds ratio represents the comparison of response to secukinumab treatment between NA and non-NA patients using the Cochran–Mantel–Haenszel test adjusted for age (< 45 or ≥ 45 years), gender, study site, body weight, treatment group, previous systemic treatment (including oral and biologic), previous biologic treatment, and baseline PASI score (≤ 20 or > 20)